قالب وردپرس درنا توس
Home / Business / Moderna said it is actively preparing to launch a vaccine

Moderna said it is actively preparing to launch a vaccine



The logo marks the headquarters of Moderna Therapeutics, which is developing a vaccine against coronavirus disease (COVID-19) in Cambridge, Massachusetts.

Brian Snyder | Reuters

The biotech company said in its third-quarter financial report released on Thursday that the company is preparing to release its potential coronavirus vaccine globally. The country has accumulated $1

.1 million in deposits from governments, waiting Drugs that may save lives.

The Cambridge, Massachusetts-based company said it is negotiating with the COVAX program supported by the World Health Organization to discuss a tiered pricing plan for its potential vaccines, temporarily calling it mRNA-1273. It has signed supply agreements in North America, the Middle East and other parts of the world.

Moderna CEO Stephane Bancel said in a press release: “We are actively preparing for the launch of mRNA-1273. We have signed many supply agreements with governments around the world.” Moderna is committed to the highest data quality standards and strict Scientific research because we will continue to work with regulatory agencies to develop mRNA-1273. “

In pre-IPO trading, Moderna’s stock price rose by more than 2%.

Moderna, the leader of the Covid-19 vaccine race, said last week that it had completed registration for its 30,000 participants in the later trials. As of last week, more than 25,650 participants had received the second of the company’s two doses of Covid-19 vaccine. The company stated that approximately 37% of the participants came from different communities, while 42% had a high risk of serious illness.

In addition, the company reported a loss of $233.6 million in the third quarter, or 59 cents per share, which was higher than the average of 43 cents per share expected by analysts surveyed by Refinitiv. The company brought in revenue of $157.9 million, higher than Wall Street’s forecast of $77.5 million.

Moderna’s vaccine was developed with the help of the National Institutes of Health and contains genetic material called messenger RNA (mRNA), which scientists hope to stimulate the immune system against the virus.

The executives made a phone call with investors at 8 am Eastern Time.

This is a developing story. Please check for updates.


Source link